Logo Logo
Switch Language to German
Boehm, Sybille; Splith, Victoria; Riedmayr, Lisa Maria; Rotzer, Rene Dominik; Gasparoni, Gilles; Nordstroem, Karl J. V.; Wagner, Johanna Elisabeth; Hinrichsmeyer, Klara Sonnie; Walter, Joern; Wahl-Schott, Christian; Fenske, Stefanie; Biel, Martin; Michalakis, Stylianos; Becirovic, Elvir (2020): A gene therapy for inherited blindness using dCas9-VPR-mediated transcriptional activation. In: Science Advances, Vol. 6, No. 34, eaba5614
Full text not available from 'Open Access LMU'.


Catalytically inactive dCas9 fused to transcriptional activators (dCas9-VPR) enables activation of silent genes. Many disease genes have counterparts, which serve similar functions but are expressed in distinct cell types. One attractive option to compensate for the missing function of a defective gene could be to transcriptionally activate its functionally equivalent counterpart via dCas9-VPR. Key challenges of this approach include the delivery of dCas9-VPR, activation efficiency, long-term expression of the target gene, and adverse effects in vivo. Using dual adeno-associated viral vectors expressing split dCas9-VPR, we show efficient transcriptional activation and long-term expression of cone photoreceptor-specific M-opsin (Opn1mw) in a rhodopsin-deficient mouse model for retinitis pigmentosa. One year after treatment, this approach yields improved retinal function and attenuated retinal degeneration with no apparent adverse effects. Our study demonstrates that dCas9-VPR-mediated transcriptional activation of functionally equivalent genes has great potential for the treatment of genetic disorders.